Skip to main content

Table 1 Summary of common oncogenic driver mutations, their corresponding testing methods and their respective inhibitors

From: Oncogenic driver mutations in lung cancer

Target Detection method Inhibitor
EGFR Direct sequencing Gefitinib, Erlotinib
Real-time PCR BIBW2992 (Afatinib)
Single-strand conformational polymorphism PF00299804 (Dacomitinib)
High-resolution melting amplicon analysis HKI-272 (Neratinib)
BPI-2009 (Icotinib)
EKB-569 (Pelitinib)
CI-1033 (Canertinib)
GW572016 (Lapatinib)
KRAS Direct sequencing Not available
Real-time PCR
Amplification refractory mutation system (ARMS)
Restriction fragment length polymorphism (RFLP)
Co-amplification at lower denaturation temperature-polymerase chain reaction (COLD-PCR)
ALK Fusion Fluorescence in situ hybridization (FISH) PF-02341066 (Crizotinib)
Immunohistochemistry (IHC) CH5424802 (AF802)
Real-time Reverse Transcription-PCR
MET Quantitative PCR PF-02341066 (Crizotinib)
Fluorescence in situ hybridization (FISH) ARQ197 (Tivantinib)
PCR-based sequencing GSK1363089 (Foretinib)
XL184 (Cabozantinib)
PF-04217903
   SGX523